Background. Diarrheal diseases are a major cause of ambulatory care visits and hospitalizations among children. Because of overlapping signs and symptoms and expensive and inefficient testing methods, the etiology of pediatric diarrhea is rarely established.
Infectious diarrhea is an important public health concern, both in resource-poor settings and in industrialized countries [1] . The World Health Organization's Global Burden of Disease study found that diarrheal diseases were the seventh leading cause of death worldwide in 2010 [2] . According to recent estimates from the US Centers for Disease Control and Prevention, approximately 179 million diarrheal illnesses occur each year in the United States, with more than 473 000 hospitalizations [3] . The impact is greatest among young children. Despite significant reductions after the introduction of the rotavirus vaccine, there are more than 105 000 hospitalizations for gastroenteritis annually among children <5 years of age [4] [5] [6] .
There have been few comprehensive studies of the etiology of gastroenteritis in the United States [7] [8] [9] [10] . Diagnostic tests are either not widely available in clinical laboratories or have limited sensitivities for many of the diarrheal pathogens that infect children [8, [11] [12] [13] [14] . With the recent advent of molecular diagnostic tests that detect multiple diarrheal pathogens, it is now possible to characterize more thoroughly the clinical epidemiology of infectious diarrhea among hospitalized children [15] . In this study, we sought to describe the clinical epidemiology of pediatric infectious diarrhea over a 2-year period using the FilmArray gastrointestinal diagnostic system (FilmArray GI panel), a rapid multiplex polymerase chain reaction (PCR)-based testing platform that simultaneously detects 23 different viral, bacterial, and protozoal targets.
Hospital. A manual chart review was performed to confirm that the children included in this study had symptoms of acute gastrointestinal illness (eg, fever, vomiting, abdominal pain, and diarrhea). Primary Children's Hospital is a 297-bed children's hospital that provides primary care for children in the Salt Lake City, Utah, region and tertiary care for children from Utah and 5 surrounding states. Stool specimens that conformed to the shape of the cup were submitted, and standard laboratory testing was performed as requested by the treating physician. Residual samples were stored at -80°C until they were tested with the FilmArray GI panel. We collected specimens between October 2010 and September 2012.
Multiple specimens were often submitted for testing over several days, which we grouped into episodes. Diarrheal episodes were determined after review by 3 of the study investigators (C. S., E. K. K., and A. T. P.). In brief, diarrheal episodes included those for which care was sought during the week before a stool specimen was obtained and the 2 weeks after collection of a stool specimen. All healthcare encounters were then reviewed manually to determine whether they were related to ongoing diarrheal illness. Diarrheal episodes were classified as outpatient, emergency, or inpatient on the basis of the highest level of care sought during the diarrheal illness episode. Thus, if a patient was hospitalized at any point during the course of his or her diarrheal episode, the episode was classified as an inpatient diarrheal episode. Only the first available stool sample submitted for diagnostic testing within each episode was tested using the FilmArray GI panel.
Chronic medical conditions were classified by using a method described by Feudtner et al [16] on the basis of International Classification of Diseases, Ninth Revision, Clinical Modification discharge diagnosis codes.
FilmArray GI Panel Pathogen Detection
The FilmArray is a rapid multiplex PCR platform with which nucleic acid extraction, nested PCR, and amplicon melt-curve analysis are performed in a closed system in 1 hour [17, 18] . The FilmArray GI pouch (investigational-use-only [IUO] version) used in this study simultaneously detects 23 diarrheagenic bacterial, viral, and protozoal agents by using pathogen-specific virulence genes or species-specific regions in housekeeping genes. The FilmArray GI panel was approved recently by the US Food and Drug Administration (FDA) for in vitro diagnostic use for 22 pathogens [4] . The FDA-cleared and IUO versions are identical except for the inclusion of Aeromonas spp. in the IUO version. Toxigenic Clostridium difficile detection was based on identification of the genes that encode an enterotoxin (tcdA) and a cytotoxin (tcdB). The pathotypes of diarrheagenic Escherichia coli were identified using pathotype-specific genetic markers: Shigatoxigenic E coli (STEC) by the detection of Shiga toxin 1 and/or 2 genes (stx1 or stx2) in association with the intimin gene (eae); enteropathogenic E coli (EPEC) by detection of the intimin gene (eae) in the absence of stx1 and/or stx2; enterotoxigenic E coli (ETEC) by genes encoding heat-labile (lt) or heat-stable (st) enterotoxins; enteroinvasive E coli (EIEC) and Shigella by the invasion plasmid antigen H gene (ipah) (EIEC and Shigella cannot be distinguished); and enteroaggregative E coli (EAEC) by pAA virulence plasmid-carried genes encoding the AAF biogenesis transcription regulator (aggR) or outer membrane protein (aatA). The FilmArray GI panel also identifies Salmonella spp., Aeromonas spp., Cryptosporidium spp., and pathogenic species of Vibrio (V cholerae, V parahaemolyticus, V vulnificus, V mimicus, V alginolyticus, and V fluvialis) and Campylobacter (C jejuni, C coli, and C upsaliensis). The viral pathogens detected include adenovirus F 40/41, astrovirus, norovirus GI/GII, rotavirus A, and sapovirus. Parasites detected include Cryptosporidium spp., Cyclospora cayetanensis, Entamoeba histolytica, and Giardia lamblia. Blinded FilmArray testing was performed in batches, and the results were not returned to the treating physician.
Statistical Analysis
Categorical variables were compared with Yates' corrected χ 2 test or Fisher's exact test, as appropriate. Continuous variables were compared by using the nonparametric Wilcoxon-MannWhitney U test. All statistical tests were 2-sided with significance defined at a P value of <.05. Statistical analyses were performed by using Stata 14.1 (Stata Corp, College Station, Texas) and R 3.2.2 (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS

Demographic Characteristics
Between October 2010 and September 2012, stool samples were collected during 1089 diarrheal illness episodes at Primary Children's Hospital. Diarrheal episodes were classified as inpatient (58%), outpatient (26%), or emergency (16%) ( Table 1 ; Supplemental Table 1 ). The median age of the study population was 5 years (interquartile range, 2-11 years), and 47% were <5 years of age. More than half (57%) of the children had an underlying chronic medical condition.
Pathogen Identification
We included 1089 diarrheal episodes among 779 children. A diarrheal pathogen was detected in 561 (52%) of 1089 episodes. A total of 752 pathogens were identified; codetection of 2 or more diarrheal pathogens occurred in 15% of the samples. A bacterial pathogen was detected in 290 (27%) samples. The most common bacterial pathogens were toxigenic C difficile (16%), EPEC (8%), STEC (4%), and ETEC (3%) (Figure 1 ). Viral pathogens were detected in 26% of the samples. Norovirus GI/GII was the most common virus and was identified in 11% of the specimens. Other viruses were also frequently detected: adenovirus F 40/41 (7%), sapovirus (6%), rotavirus A (4%), and astrovirus (2%). Protozoal pathogens were detected in 4% of the children with diarrheal episodes.
The distribution of diarrheal pathogens varied according to age (Table 2 ). Children <5 years of age were more likely than older children to have 2 or more diarrheal pathogens detected (21% vs 9%, respectively; P < .01). Toxigenic C difficile was detected in 21% of 114 infants <1 year old with a diarrheal episode and in 19% of children 2 to 4 years old as compared with 12% of the older children (P < .01). A second pathogen was identified in 15 (60%) episodes among children <1 year old in whom toxigenic C difficile was detected and in 32 (42%) of 77 episodes among children 2 to 4 years old compared with 6 (19%) of 31 episodes among children 11 to 17 years old with toxigenic C difficile (P < .01 and P = .18, respectively). Bacteria other than toxigenic C difficile were detected more commonly in episodes among children >2 years of age than among the younger children (14% vs 8%, respectively; P = .03). Overall, a virus was detected in 194 (38%) of 511 episodes among children <5 years of age compared with 92 (16%) of 578 episodes among children 5 to 17 years of age (P < .001). Each of the gastrointestinal viruses was significantly more common among diarrheal episodes in children <5 years old than among episodes in children 5 to 17 years old (P < .01 for all). Rotavirus was detected in 8% of episodes among children <1 year old (the target group for live vaccine), 5% of episodes among children 2 to 4 years of age, and 3% of episodes among children 5 to 10 years of age.
A diarrheal pathogen was identified more often among diarrheal episodes in children who presented to the emergency department (68%) than among those in an outpatient (48%) or inpatient (47%) setting (P < .01) ( Table 3 ). Viral pathogens were identified more commonly among those seen in the emergency department than in those seen in other settings (45% vs 23%, respectively; P < .001). Norovirus GI/GII was the most commonly detected pathogen among emergency department episodes (21% vs 10%; P < .001). Among diarrheal episodes in children ≥1 year of age, toxigenic C difficile was detected among 8% of emergency department episodes compared with 16% of outpatient episodes and 15% of inpatient episodes (P = .01 and .02, respectively). It was notable that norovirus GI/GII was the second most commonly detected pathogen (9%) among inpatient episodes after toxigenic C difficile (14%). Protozoa were rarely detected in inpatient diarrhea episodes (1%).
Diarrheal episodes among children with 1 or more underlying chronic medical conditions were less likely to have a pathogen identified than those with no underlying chronic conditions (45% vs 60%, respectively; P < .01) (Supplemental Table 2 ). When the analysis was restricted to inpatient episodes only, 44% of the children with 1 or more underlying chronic medical conditions had a pathogen detected compared with 55% of inpatients without an underlying chronic medical condition (P = .02). Salmonella, EPEC, STEC, Shigella/EIEC, rotavirus A, and G lamblia were significantly more common among episodes in previously healthy children.
More than 1 pathogen was detected in 160 (15%) diarrheal episodes (Supplemental Table 3 ). Two pathogens were identified in 118 (11%) of the episodes, and 3 or more pathogens were identified in 42 (4%) episodes. A virus and a bacterium were detected in 7% of the episodes. Viral-viral and bacterial-bacterial codetections were identified at similar rates (4% and 3%, respectively). Mixed viral-protozoal and bacterial-protozoal detections were identified infrequently (1% each).
Seasonality
Diarrheal episodes occurred throughout both years of the study (Figure 2 ). Bacterial detections were more common in the summer months (April through September), with distinct peaks in EPEC, STEC, and Shigella/EIEC. Viral detections were more common during the winter months (October through March) (P < .01). Toxigenic C difficile and norovirus GI/GII had less distinct seasonality, and cases were identified in every month of the study period.
DISCUSSION
This large study using a testing platform that detects 23 diarrheal pathogens provides insights into the clinical epidemiology of diarrhea among children in an industrialized country. We identified a potential pathogen in 52% of the specimens tested. The proportion of patients with an identified pathogen was higher among younger children, but this result was driven in part by detection of toxigenic C difficile, which likely represented asymptomatic carriage of the organism among infants and young children. Toxigenic C difficile (16%), diarrheagenic E coli (15%), norovirus GI/GII (11%), and adenovirus F 40/41 (7%) were the most commonly detected pathogens. Excluding the detection of toxigenic C difficile in children <1 year old, which is unlikely to represent a true infection, a potential pathogen was detected in 552 (51%) of 1089 children. Despite the marked reduction in rotavirus compared with that found in earlier studies [9, 19] , viral pathogens continued to be detected frequently and accounted for more than half of all pathogens identified in children <5 years old. It is striking that norovirus GI/GII and adenovirus F 40/41 infections were more common than rotavirus A, even among children <1 year of age.
A bacterial pathogen was identified in slightly more than 1 in 4 specimens tested, but only 59 (5%) of 1089 episodes were due to "classic" bacterial enteric pathogens that are sought in conventional stool cultures, including Campylobacter spp., Salmonella spp., Shigella spp., Yersinia enterocolitica, Plesiomonas spp., and Vibrio spp. This result is similar to those of recent prospective studies in the United States [8] [9] [10] . STEC was detected by molecular methods in 4% of children with diarrhea, which was more frequent than the detection of Salmonella spp., Shigella spp., and Campylobacter spp.; just more than half of the detections were non-E coli O157 STEC. The rate of STEC detection in our study is slightly higher than but consistent with those in other recent studies [7, 9, 10] , which may reflect the regional epidemiology of STEC or increased sensitivity of molecular detection methods [20] . Classic bacterial enteric pathogens and STEC were rarely detected (3%) in infants <1 year of age.
The most commonly detected bacterial pathogen was toxigenic C difficile; it was detected in 16% of the specimens tested. The highest isolation rates were found in infants <1 year of age (21%) and in children 1 to 4 years of age (19%). Children in these age groups have high rates of asymptomatic colonization with C difficile. Detection of C difficile in children younger than 2 years is rarely significant, and the clinical significance of detection in children 3 to 4 years old is unclear [21, 22] . In a case-control study for which a cytotoxicity assay was used, Denno et al [10] detected C difficile in 5% of children <3 years of age who presented to the emergency department with diarrhea but in 9% of the controls. Bruijnesteijn et al [23] detected C difficile by PCR in similar proportions of children <5 years of age with and without diarrhea. We did not enroll controls, but in 64% of the infants <1 year of age with toxigenic C difficile, we found a second pathogen, which suggests that most, if not all, toxigenic C difficile detections in this age group represent colonization. Among children <5 years of age with toxigenic C difficile detected, a second pathogen was identified in 47 (47%) of 101 episodes, most commonly norovirus, adenovirus F 40/41, and sapovirus (Supplemental Table 4 ). However, there is increasing evidence to support the importance of C difficile as a cause of both hospital-and community-onset diarrhea in older children [24, 25] . Among children ≥3 years old, Denno In each cell are the number of positive specimens (percentage for diarrheal pathogen). Because multiple pathogens were detected in some children, numbers add up to >100%. b Statistically significant difference in the frequency of detection relative to diarrheal episodes among children <1 year of age (P < .05).
et al [10] detected C difficile in 6% of the cases but only 1% of the controls. C difficile has been detected in 2% to 7% of children in studies of diarrheal illness who presented to an emergency department [8] [9] [10] . We identified toxigenic C difficile in 16% of children ≥1 year of age in the outpatient setting, 9% of children who presented to the emergency department, and 16% of inpatients. Additional data on the detection of toxigenic C difficile by PCR in symptomatic and asymptomatic children in different settings are needed to clarify its clinical significance and avoid overtreatment [26, 27] . A significant observation in our study was the detection of diarrheagenic E coli other than STEC in 9% of the diarrheal episodes tested, similar to the rates reported in studies of children in New Haven, Connecticut, Baltimore, Maryland, Cincinnati, Ohio, and Seattle, Washington [7, 8, 10] . We detected EAEC, defined by the presence of aggR and aatA, in 3% of the children ≤5 years of age with diarrhea. Cohen et al [7] found EAEC in 9% of children ≤5 years old in the emergency department with diarrhea and in 3% of the controls. Denno et al [10] identified EAEC in 3% of stool specimens obtained from the Seattle Children's Hospital emergency department and in 1% of their controls. Nataro et al [8] detected EAEC, defined by the presence of aatA, in 6% of children <18 years old with diarrhea in Baltimore and New Haven and in 3% of their controls. Altogether, these data suggest that EAEC is an important diarrheal pathogen among children in the United States. ETEC was detected in 11 patients in our study. Although we did not collect travel histories, several studies suggest that ETEC infection can be acquired in the United States [28] . We also detected EPEC, defined as the detection of the intimin gene eae in the absence of Shiga toxin genes, which thus includes typical and atypical EPEC, in 8% of the children. However, given the complex genetics of EPEC pathogenicity and the fact that eae-positive EPEC has been detected in similar numbers of cases and controls in some studies, the significance of EPEC detection with the FilmArray requires further delineation through case-control studies [8] .
A viral pathogen was identified in more than half of the children in whom a pathogen was identified, and viruses accounted for 62% (194 of 315) of the pathogens identified among children <5 years old. Similar to other data from the United States, norovirus GI/GII was the second most common pathogen in all age groups in our population. In prospective studies in the New Vaccine Surveillance Network, 21% of children <5 years of age who required medical attention had norovirus detected [14, 29] . In our study, we identified norovirus GI/GII in 17% of the children <5 years of age. Norovirus GI/GII was the most common pathogen identified in emergency department encounters (detected in 21% of the children). It is notable that norovirus GI/GII was present in 9% of the hospitalized children, almost as frequently as toxigenic C difficile, which emphasizes the emerging role of norovirus GI/GII in hospital-associated diarrheal illness [30, 31] .
Adenovirus F 40/41 was the second most commonly detected virus in this study. Chhabra et al [14] identified adenovirus in 12% of children <5 years of age, similar to the 9% identified among children <5 years of age in the current study. We detected adenovirus in 6% of hospitalized children, in 5% of those in an outpatient setting, and in 10% of those in the emergency department, which is comparable to the results of other studies [8] [9] [10] 32] . In marked contrast to the results of studies conducted before the era of childhood rotavirus A vaccination in which rotavirus was found in 10% to 43% of children [8] [9] [10] 33] , we identified rotavirus in only 4%. Because the FilmArray GI panel detects both wild-type and vaccine-type rotaviruses, some of the 9 detections in children <1 year of age may represent asymptomatic shedding of attenuated vaccine strains. Protozoal pathogens have not been sought consistently in diagnostic studies of sporadic diarrhea in children in the United States. G lamblia was identified in 28 (3%) of 1089 stool specimens, predominantly among children who presented to the emergency department or an outpatient clinic, which compares with the 1% reported from studies in Seattle [9, 10] .
Our study had a number of strengths. Each specimen was comprehensively tested for 23 pathogens by using a method that is equally or more sensitive and specific than standard clinical testing methods [4, 34] . It is one of the largest studies among children in an industrialized country, including 1089 episodes across 2 full calendar years among outpatients, emergency department patients, and inpatients. However, there are a number of important limitations. Pathogens can be detected in asymptomatic children. We did not enroll controls without diarrhea, which makes it difficult to determine whether the identification of a pathogen indicated that the pathogen was the cause of the child's diarrhea. Case-control studies that use new, highly sensitive multiplex assays are clearly needed to better understand the predictive value of detection. The increased sensitivity of PCR makes comparisons to other case-control studies challenging. We tested samples only from patients for whom a clinician had ordered stool testing, which resulted in potential bias. The study was conducted at 1 institution in Utah, and the distribution of diarrheal pathogens can be influenced by geography, demographics, season, and the occurrence of outbreaks. Thus, our results cannot be generalized. We did not collect comprehensive data on risk factors, symptoms, treatments, or outcomes.
This study provides a detailed picture of the pathogens identified in children who presented with diarrhea in the era of broad rotavirus vaccine use. The results highlight the utility of multipathogen testing, demonstrates the important role of viral agents of gastroenteritis, particularly norovirus, confirms the increasing prevalence of toxigenic C difficile infection among older children, and confirms that EAEC may be an important and underrecognized cause of diarrhea in US children. Additional studies are warranted to determine whether timely and sensitive detection of common viral pathogens reduces unnecessary or potentially dangerous antibiotic use.
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